Cart
sales@molnova.com
Bucumolol
CAS No. 58409-59-9
Bucumolol( —— )
Catalog No. M34535 CAS No. 58409-59-9
Bucumolol (Bucumarol) is a β-adrenergic blocking agent and a local anesthetic with antihypertensive activity and can be used to study myocardial infarction.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 296 | Get Quote |
|
| 5MG | 459 | Get Quote |
|
| 10MG | 657 | Get Quote |
|
| 25MG | 994 | Get Quote |
|
| 50MG | 1371 | Get Quote |
|
| 100MG | 1773 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBucumolol
-
NoteResearch use only, not for human use.
-
Brief DescriptionBucumolol (Bucumarol) is a β-adrenergic blocking agent and a local anesthetic with antihypertensive activity and can be used to study myocardial infarction.
-
DescriptionBucumolol (Bucumarol) is a β-adrenergic blocking agent and a local anesthetic with antihypertensive activity and can be used to study myocardial infarction.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetAdrenergic Receptor
-
RecptorAdrenergic Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number58409-59-9
-
Formula Weight305.37
-
Molecular FormulaC17H23NO4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1OC2=C(OCC(O)CNC(C)(C)C)C=CC(=C2C=C1)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
OPC-28326
OPC-28326 is a specific an α2-adrenergic receptor antagonist and acts as a peripheral vasodilator. OPC-28326 inhibits α2A-, α2B- and α2C-adrenoceptors with Ki of 2040, 285, and 55?nM, respectively.
-
Fenoterol hydrobromi...
Fenoterol hydrobromide is an orally active and selective β2-adrenoceptor agonist and bronchodilator used in the study of cardiovascular diseases such as asthma and bronchitis.
-
Silodosin
A highly potent, uroselective α1a-adrenoceptor antagonist with Ki of 36 pM; displays 583- and 56-fold lower potency against α1b and α1d respectors, respectively.
